We are a group of privately held biotech companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases.
Program: AZP-531, unacylated ghrelin analog, for the treatment of the Prader-Willi syndrome and type 2 diabètes
Status: clinical Phase II - Unpartnered
Program: Pegcrisantaspase (Asparec®, JZP-416), PEGylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia
Status: clinical Phase II/III – Partnered (Jazz Pharmaceuticals)
Program: I-HBD1, peptide with bone anabolic properties for the treatment of osteoporosis and other bone diseases
Status: Lead optimization – unpartnered